Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.465 USD | -27.50% | -26.64% | +6.25% |
Financials (USD)
Sales 2024 * | 39.1M | Sales 2025 * | 35.76M | Capitalization | 302M |
---|---|---|---|---|---|
Net income 2024 * | -82M | Net income 2025 * | -95M | EV / Sales 2024 * | 4.9 x |
Net cash position 2024 * | 110M | Net cash position 2025 * | 23.7M | EV / Sales 2025 * | 7.77 x |
P/E ratio 2024 * |
-3.83
x | P/E ratio 2025 * |
-3.62
x | Employees | 123 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.3% |
Latest transcript on Mersana Therapeutics, Inc.
1 day | -27.50% | ||
1 week | -26.64% | ||
Current month | -22.24% | ||
1 month | -39.88% | ||
3 months | -36.47% | ||
6 months | +105.42% | ||
Current year | +6.25% |
Managers | Title | Age | Since |
---|---|---|---|
Martin Huber
CEO | Chief Executive Officer | 64 | 20-04-12 |
Director of Finance/CFO | 46 | 19-07-09 | |
David Mott
CHM | Chairman | 58 | 12-07-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kristen Hege
BRD | Director/Board Member | 60 | 16-07-31 |
David Mott
CHM | Chairman | 58 | 12-07-30 |
Anna Protopapas
BRD | Director/Board Member | 59 | 15-03-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | +2.89% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 2.465 | -27.50% | 3,760,770 |
24-05-08 | 3.4 | -3.55% | 876,321 |
24-05-07 | 3.525 | +0.71% | 679,630 |
24-05-06 | 3.5 | +1.16% | 694,529 |
24-05-03 | 3.46 | +2.98% | 1,189,390 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.25% | 302M | |
+2.97% | 108B | |
+10.21% | 104B | |
+1.57% | 22.33B | |
-12.77% | 22.19B | |
-7.05% | 18.69B | |
-37.64% | 17.74B | |
-6.50% | 17.64B | |
+6.00% | 14.05B | |
+37.20% | 12.51B |
- Stock Market
- Equities
- MRSN Stock